Summary
Apigenin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Ovarian Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Ovarian Cancer. No registered clinical trial in this database tests Apigenin specifically in Ovarian Cancer. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2007 to 2009. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Ovarian Cancer ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: No spontaneous remission; 5-year survival Stage I: 90%; Stage III/IV: 25-30%; most patients (75%) present at Stage III-IV.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 24.0 (trials 0.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Apigenin to Ovarian Cancer in the current OSMF trial extract.
Published literature
- Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older womenWang L, Lee IM, Zhang SM et al. · The American journal of clinical nutrition · 2009 · PMID 19158208
- Clinical trial publication A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancerGates MA, Tworoger SS, Hecht JL et al. · International journal of cancer · 2007 · PMID 17471564
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Apigenin approved for Ovarian Cancer?
Apigenin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Ovarian Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Ovarian Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Apigenin in clinical trials for Ovarian Cancer?
No registered clinical trial in this database tests Apigenin specifically in Ovarian Cancer. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Apigenin in Ovarian Cancer?
The record for Apigenin in Ovarian Cancer rests on 2 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.